Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Indoleamine 2,3-dioxygenase (IDO) is an important therapeutic target for the treatment of diseases such as cancer that involve pathological immune escape. We have used the evolutionary docking algorithm EADock to design new inhibitors of this enzyme. First, we investigated the modes of binding of all known IDO inhibitors. On the basis of the observed docked conformations, we developed a pharmacophore model, which was then used to devise new compounds to be tested for IDO inhibition. We also used a fragment-based approach to design and to optimize small organic molecule inhibitors. Both approaches yielded several new low-molecular weight inhibitor scaffolds, the most active being of nanomolar potency in an enzymatic assay. Cellular assays confirmed the potential biological relevance of four different scaffolds.

Original publication

DOI

10.1021/jm9014718

Type

Journal article

Journal

J Med Chem

Publication Date

11/02/2010

Volume

53

Pages

1172 - 1189

Keywords

Animals, Cell Proliferation, Cells, Cultured, Drug Design, Enzyme Inhibitors, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase, Kynurenine, Mice, Models, Molecular, Small Molecule Libraries, Structure-Activity Relationship, Tryptophan